Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain + Acetylsalicylic Acid (Aspirin, BAYE4465) + Lidocain + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Common Cold
Conditions
Common Cold, Pharyngitis, Tonsillitis
Trial Timeline
Nov 30, 2004 โ May 28, 2005
NCT ID
NCT01361399About Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain + Acetylsalicylic Acid (Aspirin, BAYE4465) + Lidocain + Placebo
Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain + Acetylsalicylic Acid (Aspirin, BAYE4465) + Lidocain + Placebo is a phase 3 stage product being developed by Bayer for Common Cold. The current trial status is completed. This product is registered under clinical trial identifier NCT01361399. Target conditions include Common Cold, Pharyngitis, Tonsillitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01361399 | Phase 3 | Completed |
Competing Products
20 competing products in Common Cold